XLO compared with LKFT: revenue, margins and what each company keeps, and the suppliers and customers both name

XLOXilio Therapeutics, Inc.

Mkt capRevenueRevenue

LKFTLakefront Biotherapeutics NV

Mkt capRevenueRevenue

Compare

XLOXilio Therapeutics, Inc.

LKFTLakefront Biotherapeutics NV

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

XLO1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−1.42%—

LKFT

No earnings history for LKFT.

= impliedXLO realized, solidLKFT realized, hatchedOne scale, both sides: full bar = 2%× = |realized| ÷ impliedSource: market data

XLOXilio Therapeutics, Inc.

8.66▲+1.88%· post 8.66

Mkt cap$167.3MRevenue$19MQ2 FY26Revenue$44MFY25

LKFTLakefront Biotherapeutics NV

33.44▼−0.36%· post 33.45

ClosedNov 6 '26

Mkt cap$2.2BRevenue—Revenue—

Compare

ClosedNov 6 '26

XLOXilio Therapeutics, Inc.

LKFTLakefront Biotherapeutics NV

8.66▲+1.88%post 8.66

Price

33.44▼−0.36%post 33.45

$167.3M

Mkt cap

$2.2B

Q2 FY26$19M

Revenue

—

FY25$44M

Revenue

—

XLO8.66▲+1.88%vsLKFT33.44▼−0.36%ClosedNov 6 '26